AbbVie Sees $2M in Unusual Options Premium as ITM Puts Dominate the Flow
By TrendSpider Editor
The forward setup for ABBV is layered. The stock has pulled back meaningfully from its 52-week high of $244.81, sitting roughly $17 below that peak, while holding comfortably above its 52-week low of $181.735. The concentration of in-the-money put premium at the $280 strike is notable because it imp
AbbVie Sees $2M in Unusual Options Premium as ITM Puts Dominate the Flow
AbbVie Inc. (ABBV) is drawing attention in the options market Friday, with $2,038,278 in total premium flowing across three unusual contracts, two of which are deep in-the-money puts at the $280 strike. Shares are trading at $227.17, up 1.08% on the session, within a 52-week range of $181.735 to $244.81. Despite the modest intraday gain, the options positioning tells a more cautious story beneath the surface.Key Drivers of the ABBV Stock Move
- Main Catalyst: Three unusual options contracts have triggered a combined $2,038,278 in total premium, with the dominant activity concentrated in two put contracts on the $280 strike expiring September 18, 2026. A block of 235 contracts and a follow-on block of 118 contracts, both ITM puts, account for the overwhelming majority of the premium flow.
- Bull Case: A single call contract at the $230 strike expiring July 31, 2026, represents bullish positioning just above the current price of $227.17. At an open interest usage of 667% above existing OI, the call shows conviction, even if it is dwarfed by the put activity in raw dollar terms.
- Bear Case: The two $280 put contracts, both expiring September 18, 2026, carry open interest ratios of 1,000% and represent $1,337,150 and $672,600 in premium, respectively. Being in-the-money with the stock trading at $227.17 means these contracts are already carrying intrinsic value, suggesting a trader or institution is either hedging a large long position or making a directional bet that ABBV remains well below $280 through mid-September.
The forward setup for ABBV is layered. The stock has pulled back meaningfully from its 52-week high of $244.81, sitting roughly $17 below that peak, while holding comfortably above its 52-week low of $181.735. The concentration of in-the-money put premium at the $280 strike is notable because it implies protection or profit above a level the stock has not traded at within the past year, which points toward large institutional hedging rather than a simple directional short. Traders will be watching whether today's 1.08% price gain can build momentum toward the $230 to $244.81 resistance zone, or whether the heavyweight put positioning reflects better-informed expectations of continued pressure on the shares through the summer months.
ABBV Unusual Options Activity
- Contract 1: Call, $230 strike, expiring July 31, 2026 | Volume: 40 | Open Interest: 667% above existing OI | Out of the Money
- Contract 2: Put, $280 strike, expiring September 18, 2026 | Volume: 235 | Open Interest: 1,000% above existing OI | In the Money | Premium: $1,337,150
- Contract 3: Put, $280 strike, expiring September 18, 2026 | Volume: 118 | Open Interest: 1,000% above existing OI | In the Money | Premium: $672,600
Total unusual premium across all three contracts reached $2,038,278, with put contracts accounting for the dominant share of flow. The repeat positioning on the same $280 strike and expiration across two separate blocks suggests a deliberate and potentially staged entry into the position.
ABBV Seasonality
Mid-June through mid-September has historically been an active period for pharmaceutical names as pipeline updates, conference presentations, and mid-year guidance revisions can drive volatility. The September 18, 2026 expiration on the dominant put contracts captures this window in full, which may be a deliberate choice by whoever is behind the flow.
ABBV Relative Performance
ABBV's 1.08% gain on Friday puts it in modestly positive territory on the session. With a current price of $227.17 sitting in the upper half of its 52-week range of $181.735 to $244.81, the stock has demonstrated resilience relative to broader healthcare sector volatility, though it remains approximately 7.2% below its 52-week high, leaving room for recovery or further consolidation depending on how the fundamental backdrop evolves through the summer.